After TauRx Pharmaceutics’ investigational Alzheimer’s treatment hydromethylthionine mesylate (HMTM) was found to slow the disease’s progression it could, if approved, become the first oral treatment targeting the tau protein.

www.pmlive.com/awards/communique/book_a_table

Two biotech firms and a radiochemistry company will develop next-generation targeted alpha-therapies to treat various forms of cancer.

PharmaRole.com

Welcome to the April/May issue of Pharmafocus, which arrives at a time when established scientific and trade norms are being upended under the current US administration. So, it’s timely that a new report should emerge that examines pharmaceutical trade across Europe and delves into the largest international markets for our industry (page 4).

Pharmafocus April/May 2025 - Magazine Contents

Belgium biotechnology company Galapagos has made changes at the top as it prepares to split into two separate entities.

Germany, France, Belgium, Italy and the Netherlands account for the majority of trade in pharmaceutical products across Europe, according to a new report.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Moderna’s plans to manufacture commercial mRNA vaccines at its existing facility in Harwell in Oxfordshire.

Besins Healthcare has launched in the UK its new treatment, based on progesterone, to prevent miscarriage.

Novo Nordisk’s diabetes treatment Rybelsus (semaglutide) has been found to significantly reduce the risk of major adverse cardiovascular events (MACE).

Indian biotechnology company Eyestem Research has achieved successful results from a phase 1 trial of Eyecyte-RPE, its potential therapy for a rare, advanced form of dry age-related macular degeneration (AMD).

Corcept Therapeutics’ oral ovarian cancer drug relacorilant has improved progression-free survival in the ROSELLA trial.

Johnson & Johnson’s Darzalex (daratumumab) could help patients with newly diagnosed multiple myeloma (NDMM) approach normal life expectancy without their disease progressing.

US regulators have granted a fast track designation to Sanofi’s mRNA chlamydia vaccine, putting it in line for development benefits and an expedited review.

San Diego-headquartered biotechnology company GRI Bio has strengthened its global intellectual property portfolio with the addition of two new patents.

Japan’s Ministry of Health, Labour and Welfare has authorised the marketing and manufacturing of Sanofi and Regeneron’s chronic obstructive pulmonary disease (COPD) treatment Dupixent (dupilumab).

The Scottish Medicines Consortium (SMC) has approved Ipsen’s Iqirvo (elafibranor) in NHS Scotland to treat the rare liver disease primary biliary cholangitis (PBC).

Global temperature-sensitive packing and digital solutions provider Cold Chain Technologies (CCT) has acquired Australia's Global Cold Chain Solutions (GCCS) to expand its Asia Pacific presence and capabilities.

Nuclear medicine company Curium Pharma has acquired Monrol (Eczacıbaşı-Monrol Nuclear Products) to expand its presence in the sector.

Finnish health and social care provider Mehiläinen has agreed to acquire Eastern European healthcare companies Regina Maria and MediGroup.

Swedish biotechnology company Asgard Therapeutics has appointed Shane Olwill as chief development officer (CDO) to further its work on in vivo direct cell reprogramming for cancer immunology.

Ellab has appointed Gergely Sved as its new chief executive officer (CEO) following the departure of Ludvig Enlund.

Berlin-based ProBioGen has appointed its former chief operating officer (COO) Alfred Merz to be its new chief executive officer (CEO), a role he had previously been holding on an interim basis.

CluePoints has appointed Usama Dar as its new chief product and technology officer.

AAX Biotech has made two key appointments as it seeks to further develop its research efforts and business presence.

UK-based consultancy-led organisation Coronado Research has announced that it has appointed Gary Lyons as executive vice president (EVP) for medical affairs.

21GRAMS and Havas Lynx lead the charge at the PM Society Awards for pharma marketing and healthcare communications

From prostate cancer to hormonal health, many areas of men’s health require more attention. As male life expectancy and healthy lifespan continue to lag behind, Charlie Bryant at Androlabs explores how pharma could help improve this by shifting its focus from treatment to prevention

Dr Werner Engelbrecht at Veeva Systems discusses how compliance can be turned into a competitive advantage with connected platforms and data, AI-driven efficiencies and new patient-centric models

Tina Backhouse from Theramex on the treatment access challenges women face

Five Facts about mental health

WWW.FLYPHARMAEUROPE.COM